Novocure GmbH

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.novocure.com

Clinical Trials

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Device: NovoTTF-200T
Drug: Pembrolizumab

First Posted Date: 2024-08-19

Last Posted Date: 2024-10-22

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 69

Registration Number: NCT06558799

Locations: 🇦🇹
Universitätsklinik f. Innere Medizin III, Salzburg, Austria

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Phase 3

Recruiting

Conditions: Glioblastoma

Interventions: Device: Optune® device
Drug: Temozolomide
Drug: Pembrolizumab
Drug: Placebo

First Posted Date: 2024-08-16

Last Posted Date: 2024-12-20

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 741

Registration Number: NCT06556563

Locations: 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸
Swedish Medical Center, Seattle, Washington, United States
🇺🇸
UF Health Neuromedicine, Gainesville, Florida, United States

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Phase 3

Recruiting

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Device: NovoTTF-200T
Drug: Pembrolizumab
Drug: Platinum based chemotherapy

First Posted Date: 2024-01-22

Last Posted Date: 2024-11-22

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 734

Registration Number: NCT06216301

Locations: 🇺🇸
St. Jude Herritage Medical Group, Fullerton, California, United States
🇺🇸
Edward Cancer Center, Naperville, Illinois, United States
🇪🇸
Hospital Universitario Arnau de Vilanova, Lleida, Spain

and more 27 locations

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study

Recruiting

Conditions: Pleural Mesothelioma

Interventions: Device: TTFields

First Posted Date: 2022-09-14

Last Posted Date: 2024-12-04

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 198

Registration Number: NCT05538806

Locations: 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Evangelisches Krankenhaus Herne, Herne, Germany
🇩🇪
GEHO Muenster, Muenster, Germany

and more 18 locations

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge

Not Applicable

Completed

Conditions: COVID-19

Interventions: Device: NovoTTF-100L

First Posted Date: 2021-07-07

Last Posted Date: 2021-07-07

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 10

Registration Number: NCT04953234

Locations: 🇮🇱
Hadassah Medical Center, Jerusalem, Israel

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Device: NovoTTF-200T
Drug: Pembrolizumab (MK-3475) 200 mg

First Posted Date: 2021-05-19

Last Posted Date: 2023-10-06

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 100

Registration Number: NCT04892472

Locations: 🇺🇸
University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States
🇺🇸
OptumCare Cancer Care, Las Vegas, Nevada, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States

and more 21 locations

Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Device: TTFields

First Posted Date: 2020-07-30

Last Posted Date: 2024-08-16

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 25

Registration Number: NCT04492163

Locations: 🇨🇿
Nemocnice Na Homolce, Prague, Czechia

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase 3

Completed

Conditions: Nonsmall Cell Lung Cancer
NSCLC

Interventions: Device: NovoTTF-200T
Drug: Immune checkpoint inhibitors or docetaxel

First Posted Date: 2016-11-25

Last Posted Date: 2024-10-21

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 276

Registration Number: NCT02973789

Locations: 🇺🇸
Clinical Oncology Associates, Farmington Hills, Michigan, United States
🇺🇸
Dallas VA Medical Center, Dallas, Texas, United States
🇺🇸
Renown Regional Medical Center Institute for Cancer, Reno, Nevada, United States

and more 121 locations

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Phase 3

Active, not recruiting

Conditions: Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

Interventions: Device: NovoTTF-200M device
Other: Best Standard of Care

First Posted Date: 2016-07-13

Last Posted Date: 2023-03-10

Lead Sponsor: NovoCure GmbH

Target Recruit Count: 270

Registration Number: NCT02831959

Locations: 🇺🇸
Piedmont Brain Tumor Center, Atlanta, Georgia, United States
🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 124 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy